Literature DB >> 19322187

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Tevfik Ecder1, Robert W Schrier.   

Abstract

Cardiovascular problems are a major cause of morbidity and mortality in patients with autosomal-dominant polycystic kidney disease (ADPKD). Hypertension is a common early symptom of ADPKD, and occurs in approximately 60% of patients before renal function has become impaired. Hypertension is associated with an increased rate of progression to end-stage renal disease and is the most important potentially treatable variable in ADPKD. Left ventricular hypertrophy, which is a powerful, independent risk factor for cardiovascular morbidity and mortality, also occurs frequently in patients with ADPKD. Both hypertension and left ventricular hypertrophy have important roles in cardiovascular complications in these individuals. Moreover, biventricular diastolic dysfunction, endothelial dysfunction, increased carotid intima-media thickness, and impaired coronary flow velocity reserve are present even in young patients with ADPKD who have normal blood pressure and well-preserved renal function. These findings suggest that cardiovascular involvement starts very early in the course of ADPKD. Intracranial and extracranial aneurysms and cardiac valvular defects are other potential cardiovascular problems in patients with ADPKD. Early diagnosis and treatment of hypertension, with drugs that block the renin-angiotensin-aldosterone system, has the potential to decrease the cardiovascular complications and slow the progression of renal disease in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322187      PMCID: PMC2720315          DOI: 10.1038/nrneph.2009.13

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  95 in total

1.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

2.  The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Svend Strandgaard; Anne-Lise Kamper; Giuseppe Maschio; Gavin Becker; Ronald D Perrone; Andrew S Levey
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

3.  Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease.

Authors:  Edgar A F de Almeida; Eduardo I de Oliveira; José A Lopes; Ana G Almeida; M Martins Prata
Journal:  Am J Kidney Dis       Date:  2006-04       Impact factor: 8.860

4.  Vascular expression of polycystin.

Authors:  M D Griffin; V E Torres; J P Grande; R Kumar
Journal:  J Am Soc Nephrol       Date:  1997-04       Impact factor: 10.121

5.  Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease.

Authors:  L Pérez-Oller; R Torra; C Badenas; M Milà; A Darnell
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

6.  Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.

Authors:  Kikuo Nutahara; Eiji Higashihara; Shigeo Horie; Kouichi Kamura; Ken Tsuchiya; Toshio Mochizuki; Tatsuo Hosoya; Tomohiro Nakayama; Norio Yamamoto; Yoshio Higaki; Toshiko Shimizu
Journal:  Nephron Clin Pract       Date:  2005

7.  Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population.

Authors:  Catherine L Kelleher; Kim K McFann; Ann M Johnson; Robert W Schrier
Journal:  Am J Hypertens       Date:  2004-11       Impact factor: 2.689

8.  Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus.

Authors:  R O Estacio; B W Jeffers; E P Havranek; D Krick; M Raynolds; R W Schrier
Journal:  Am J Hypertens       Date:  1999-06       Impact factor: 2.689

9.  Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome.

Authors:  Alireza Abdollah Shamshirsaz; Abdollah Shamshirsaz; Mir Reza Bekheirnia; Reza M Bekheirnia; Mohammad Kamgar; Ann M Johnson; K McFann; Melissa Cadnapaphornchai; Niloofar Nobakhthaghighi; N N Haghighi; Robert W Schrier
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

10.  Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease.

Authors:  Huseyin Oflaz; Sabahat Alisir; Banu Buyukaydin; Orhan Kocaman; Faruk Turgut; Sule Namli; Burak Pamukcu; Aytac Oncul; Tevfik Ecder
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

View more
  80 in total

1.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

3.  A case of cerebral infarction caused by painless acute aortic dissection in autosomal dominant polycystic kidney disease.

Authors:  Shintaro Yamaguchi; Shu Wakino; Hirobumi Tokuyama; Hiroshi Itoh
Journal:  CEN Case Rep       Date:  2020-01-27

4.  Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function.

Authors:  Cuma Bulent Gul; Abdulmecit Yildiz; Alparslan Ersoy; Serdar Kahvecioglu; Burak Asiltas; Fatih Yildirim; Selime Ermurat; Saim Sag; Aysegul Oruc; Sumeyye Gullulu; Mustafa Gullulu
Journal:  Int Urol Nephrol       Date:  2015-06-06       Impact factor: 2.370

Review 5.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

6.  Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.

Authors:  Kristen L Nowak; Heather Farmer; Melissa A Cadnapaphornchai; Berenice Gitomer; Michel Chonchol
Journal:  Nephrol Dial Transplant       Date:  2017-02-01       Impact factor: 5.992

7.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

Review 8.  A cut above (and below): Protein cleavage in the regulation of polycystin trafficking and signaling.

Authors:  Valeria Padovano; Kavita Mistry; David Merrick; Nikolay Gresko; Michael J Caplan
Journal:  Cell Signal       Date:  2020-04-10       Impact factor: 4.315

9.  Epicardial Fat Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Antonio Concistrè; Luigi Petramala; Gianmarco Scoccia; Susanna Sciomer; Valeria Bisogni; Vincenza Saracino; Gino Iannucci; Silvia Lai; Daniela Mastroluca; Gianluca Iacobellis; Claudio Letizia
Journal:  Cardiorenal Med       Date:  2018-05-03       Impact factor: 2.041

Review 10.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.